Veriheal

JANUARY 24, 2023

But recent news of the DEA’s approval of a cocaine derivative for Parkinson’s disease research has left us scratching our heads. After receiving a petition three years prior, the DEA finally answered with action, making plans to deschedule [18F]FP-CIT , a controlled substance derived from cocaine.

DEA 98

DEA Treatment Medicine Pets 98

Leafly

MAY 10, 2022

Many were arrested protesting the DEA's decision to not recognize the Right To Try law, allowing psilocybin use for terminally ill patients looking to ease end-of-life anxiety and distress. The post Protestors of psilocybin ban arrested at DEA headquarters appeared first on Leafly.

DEA 84

DEA Patients Law 84

Medical Marijuana Program Connection

MAY 2, 2024

The US Drug Enforcement Agency (DEA) is moving forward with plans to move marijuana from a Schedule I to a Schedule III controlled substance under the Controlled Substance Act (CSA), the US Department of Justice officials announced this week. First reported by the Associated Press and since confirmed by Medscape. Read More

DEA 53

DEA Marijuana Safety Patients 53

Leafly

APRIL 6, 2020

Prescription CBD tincture Epidiolex is coming to more patients. The post DEA loosens rules on prescription CBD drug Epidiolex appeared first on Leafly. Cost: $32,500 per year.

DEA 123

DEA CBD Tincture Patients 123

Project CBD

NOVEMBER 8, 2021

Psilocybin, the psychedelic mushroom extract, has been fast-tracked by the FDA to treat depression, but doctors still can’t use it in their practice.

DEA 150

DEA Patients Extraction 150

NORML

APRIL 30, 2024

“It is significant for these federal agencies, and the DEA and FDA in particular, to acknowledge publicly for the first time what many patients and advocates have known for decades: that cannabis is a safe and effective therapeutic agent for tens of millions of Americans.”

DEA 353

DEA Patients Cannabis Policy 353

Cannabis Law Report

AUGUST 12, 2021

Drug Enforcement Administration’s (DEA) refusal to accommodate state and federal right to try laws. US DEA , No. RTT laws permit certain patients who have been diagnosed with life-threatening diseases or conditions access to investigational medications not yet approved for general use by the U.S. 21-70544 (9th Cir.),

DEA 105

DEA Medicine Food Patients 105

NewsMunchies

MAY 20, 2021

This action by the DEA means researchers will be able to study marijuana from more than one grower. To the extent these MOAs are finalized, DEA anticipates issuing DEA registrations to these manufacturers. million for Ole Miss to grow so it can be doled out in grams to scientists. Rate this blog post.

DEA 98

DEA Chronic Pain Terpenes Packaging 98

Cannabis Law Report

FEBRUARY 24, 2023

DEA extends many telemedicine flexibilities adopted during the COVID-19 PHE with appropriate safeguards WASHINGTON – Today, the Drug Enforcement Administration announced proposed permanent rules for the prescribing of controlled medications via telemedicine, expanding patient access to critical therapies beyond the scheduled end of the COVID-19 (..)

DEA 52

DEA Therapy Access Patients 52

Americans for Safe Access

APRIL 19, 2022

When we started Americans for Access, we were facing paramilitary style raids from the DEA, only 8 states had passed laws creating criminal exemptions for medical cannabis patients, the DEA was still saying that cannabis was a gateway drug and there was no legal access anywhere!

DEA 238

DEA Access Patients Law 238

Veriheal

JUNE 29, 2021

While they offer approved clinical trials that can offer patients the ability to try potential therapeutic options, many patients are unable to participate in clinical trials, and this is where the importance of the Right to Try programs comes into play. A Push by Patients. Patients Are Not In This Alone.

Therapy 55

Therapy DEA Patients Clinical Trials 55

Cannabis Law Report

DECEMBER 7, 2021

On November 16, 2021, the Drug Enforcement Agency (DEA) issued an advance notice of proposed rulemaking , exploring whether or not to create new federal regulations governing the practice of telepharmacy. The DEA’s notice provides the industry with an opportunity to provide insight and feedback that may help shape the new regulations.

DEA 52

DEA Patients Therapy Access 52

WeedAdvisor

JULY 4, 2019

Despite mounting evidence into cannabis’ therapeutic benefits, the DEA continues to close its eyes and plug its ears, constantly claiming that there is not enough research to support its medicinal value, according to Marijuana Moment. It could be argued that the DEA is hesitant for the sake of public safety.

DEA 111

DEA Research and Development Clinical Trials Cannabis 111

The Cannigma

JUNE 14, 2021

All that is about to change, thanks to a change at the DEA , which cultivators and industry experts say will be monumental for cannabis research, medical marijuana patients, and potentially the broader legal status of the plant itself. “We BRC) told The Cannigma this week. Junk’ cannabis ‘ill-suited for clinical trials’. Shutterstock).

DEA 133

DEA Research and Development Clinical Trials Pharmaceutical 133

MJ Business Attorneys

JUNE 29, 2018

Epidiolex is the first drug the FDA has approved that contains a substance derived from marijuana, and it is also the first drug approved by the FDA to be used to treat patients with Dravet syndrome. Moreover, the ball is in the Drug Enforcement Agency’s (DEA) court. In the recent case Hemp Industries Associations v.

DEA 113

DEA CBD Pharmaceutical Research and Development 113

Canna Law Blog

MAY 7, 2020

What you may not know is that the federal government actually has its own stash of cannabis for limited patient distribution and limited research purposes that it houses at the University of Mississippi (a/k/a) Ole Miss in Oxford, Mississippi.

DEA 72

DEA Research and Development Cultivation Supply Chain 72

Cannabis Law Report

JUNE 3, 2021

A Seattle palliative care physician has filed a lawsuit against the DEA, contesting its decision to ban psilocybin for use by terminally ill patients. Background of the Case. Read more .

DEA 98

DEA Access Clinical Trials Patients 98

Cannabis Law Report

FEBRUARY 5, 2022

Drug Enforcement Administration (DEA) this week challenging the government’s Schedule I classification of psilocybin, the main psychoactive component of psychedelic mushrooms. Seattle Doctor Files DEA Petition To Reschedule Psilocybin For Medical Use. Marijuana Moment. As part of the suit, attorneys general from eight U.S.

DEA 52

DEA Patients Marijuana 52

Cannabis Law Report

MAY 25, 2021

Marijuana Moment reports A bipartisan group of attorneys general from eight U.S. states and the District of Columbia has sided… Read More.

DEA 97

DEA Patients Marijuana 97

Veriheal

FEBRUARY 1, 2021

The filing is backed by MAPS (Multidisciplinary Association for Psychedelic Studies) and calls on the DEA to answer a four-year-old filing requesting approval of his application to become a federally registered marijuana cultivator. Back in 2016, the DEA said they were starting the process of approving “additional marijuana cultivators.”

DEA 63

DEA Therapy Cultivation Media 63

SpeedWeed

SEPTEMBER 4, 2021

The DEA published a new document in the Federal Register on September 2 requesting an increase in production for certain Schedule I and Schedule II substances so that it can initiate more research studies. . DEA firmly believes in supporting regulated research of schedule I controlled substances. Some states in the U.S.

DEA 52

DEA Research and Development Clinical Trials Extraction 52

SpeedWeed

MAY 18, 2021

Drug Enforcement Administration (DEA) quietly made an announcement that’s expected to have a profound and long-lasting impact on cannabis research and development in the United States. For years, NIDA and the DEA have promised to open up the sourcing of federally-approved research cannabis. DEA finally relents.

DEA 52

DEA Research and Development Data Cannabis 52

NORML

FEBRUARY 18, 2020

The latest offense is his recently released 2021 federal budget proposes slashing all legal protection for state medical marijuana programs and potentially jeopardizing the patients that rely on them. No patient should have to worry about losing access to cannabis treatment options. The data speaks for itself.

Marijuana 355

Marijuana DEA Programs Patients 355

Veriheal

JUNE 22, 2021

While the federal government still holds medical cannabis or even recreational cannabis from the people clinging to years of draconian prohibition, they are allowing certain individuals to work with the DEA and FDA to study antimicrobial properties of cannabinoid therapies being applied to fighting bacteria such as MRSA.

DEA 59

DEA Access Therapy Cannabinoids 59

Cannabis Law Report

APRIL 4, 2022

Congress, signed into law by President Trump, with 41 state enactments, give terminally ill patients access to experimental medicines still in development? The filing, she explained, was to clarify, “Is the DEA going to comply with duly enacted state and federal law and allow access to psilocybin therapy?” Read more at.

Access 52

Access Patients DEA Research and Development 52

Cannabis Law Report

OCTOBER 4, 2021

One of the known beneficial uses of psilocybin is as a palliative care tool for patients with advanced illness who suffer from anxiety and/or depression. Adult Oregonians will be able to access psilocybin therapy under the PSA beginning in January 2023; patients with advanced illness are among those who may benefit from this therapy.

Therapy 52

Therapy Patients Law Clinical Trials 52

Cannabis Law Report

SEPTEMBER 12, 2021

I certainly hope that other states follow Nevada’s lead and provide reassurances to licensed veterinarians that they can administer CBD or talk about it with patients without fear of facing disciplinary proceedings,” he said. But do medical cannabinoids actually help animal patients? Although products containing 0.3% A simple question.

Patients 105

Patients Pets Seed-To-Sale Cannabinoids 105

Cannabis Law Report

JUNE 12, 2021

MONTEREY, CA – Biopharmaceutical Research Company (BRC), an active Drug Enforcement Administration (DEA) license holder, and CURE Pharmaceutical Holding Corp. CURE has established itself as a leader in the oral application of cannabis-derived treatments, and we know we’ll be able to bring a lot of value to patients together.”.

DEA 59

DEA Pharmaceutical Research and Development Compliance 59

Cannabis Law Report

JUNE 3, 2019

Plaintiffs in the case, including medical marijuana patients, told the 2nd U.S. Circuit Court of Appeals that the DEA’s refusal to reschedule cannabis damaged their health and that the federal agency should remove cannabis from Schedule 1. Federal appeals court to DEA: Reconsider marijuana’s Schedule 1 status.

DEA 59

DEA Patients Marijuana Cannabis 59

Cannabis Law Report

NOVEMBER 22, 2019

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. “Patients will benefit from cGMP-quality therapies in an accessible and efficient format.”. . Most recently the FDA awarded MMJ International Holdings ?

DEA 66

DEA Clinical Trials THC Research and Development 66

Cannabis Law Report

NOVEMBER 20, 2021

he Alabama State Board of Medical Examiners Thursday announced draft rules to govern how physicians can recommend medical cannabis to eligible patients. The draft rules would require physicians to obtain an annual certification permit from the Alabama Board of Medical Examiners if they want to recommend a patient to use medical cannabis.

Patients 52

Patients DEA Dispensary Conditions 52

Cannabis Law Report

FEBRUARY 8, 2022

The law, which has some doctors saying they have stopped working with medical cannabis patients altogether, requires that patients obtain written “certifications” from doctors in order to access marijuana concentrates over a new daily limit. It is unknown how many doctors have decided to stop working with cannabis patients.

Patients 52

Patients Legislation Concentrates DEA 52

Marijuana Lawyer Blog

JANUARY 12, 2019

As our Los Angeles marijuana patient attorneys can explain, the crux of the argument by plaintiffs of the claim, first filed in 2017, is that the designation ignores the merits of the drug for medicinal purposes. Defendants are acting-Attorney General Matthew Whitaker, the acting director of the DEA and the federal government.

DEA 40

DEA Patients Epilepsy Medicine 40

WeedAdvisor

JUNE 1, 2019

The court, citing concerns over marijuana’s Schedule I status and its impact on medical users who need it most, essentially issued an ultimatum to the DEA. Like a child who does not want to clean his or her room, the DEA simply refuses to take any major action, despite the whirlwind of reforms surrounding them on a daily basis.

DEA 55

DEA Marijuana History Cannabis 55

United Patients Group

JANUARY 15, 2023

However, the DEA and FDA still consider CBD a drug regulated under the Schedule I classification. The DEA definition of a Schedule 1 substance is : Schedule I drugs, substances, or chemicals are defined as drugs with no currently accepted medical use and a high potential for abuse. Book a consultation today.

THC 117

THC CBD DEA Cannabinoids 117

NORML

JANUARY 17, 2019

As the result of a lawsuit, DEA Administrative Law Judge Mary Ellen Bittner in 2007 ruled that expanding the pool of federally licensed providers would be “in the public interest.” The agency ultimately rejected her decision. Click here to send a message to your federal lawmaker and urge them to support the measure. .

Clinical Trials 232

Clinical Trials Legislation DEA Strains 232

Cannabis Law Report

MAY 10, 2022

Activists staged a demonstration outside of the Drug Enforcement Administration (DEA) headquarters in Virginia on Monday, demanding that the agency allow terminally ill patients to access psilocybin therapy. Patients, veterans and key advocates participated in the demonstration. Marijuana Moment reports. aeidinger) May 9, 2022.

DEA 52

DEA Therapy Access Patients 52